Atopic dermatitis (AD) is a common, chronic inflammatory skin disease that oftentimes requires complex therapy. Poor adherence is a major barrier to AD treatment success. An interspecialty, virtual roundtable panel was held, through which clinical dermatologists, allergists, and behavioral and social psychologists discussed AD management and adherence. Relevant literature was reviewed, and the content of this article was organized based on the roundtable discussion. Current guidelines for AD treatment include maintenance and acute therapy for mild-to-severe AD. Therapy is often complex and requires significant patient involvement, which may contribute to poor treatment adherence. Behavioral and social psychology strategies that may help improve adherence include scheduling timely follow-up appointments, using a clearly written eczema action plan (EAP), reducing perceived treatment burden, utilizing anchoring techniques, sharing anecdotes, and rewarding children using positive reinforcement and stickers. There are multiple practical ways by which providers can improve both the management and treatment adherence of patients with AD.
Bibliografisk noteFunding Information:
Dr. Steven Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate and National Psoriasis Foundation. He is founder and majority owner of http://www.DrScore.com and founder and part owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. Dr. Alan Fleischer is a consultant for Boerhringer-Ingelheim, Incyte, Qurient, SCM Lifescience, Syneos and Trevi. He is an investigator for Galderma and Trevi. The authors otherwise declare no conflicts of interests. Heather L. Tier, Esther A. Balogh, Arjun M. Bashyam, Jonathan M. Spergel, EJ Masicampo, Lara K. Kammrath and Lindsay C. Strowd have nothing to disclose.
Sponsorship for this study was funded by Pfizer Inc. Pfizer Inc. New York, NY USA. The Pfizer funds awarded to the institution included the funds for publication fees.
© 2021, The Author(s).
Copyright 2021 Elsevier B.V., All rights reserved.